Mitomycin- and calcineurin-associated HUS, endothelial dysfunction and endothelial repair: a new paradigm for the puzzle?
Shah
Ronak
R
Division of Nephrology, Hypertension and Transplantation, Department of Medicine, University of Florida, Gainesville, FL 32610-0267, USA.
Beem
Elaine
E
Sautina
Laura
L
Zharikov
Sergey I
SI
Segal
Mark S
MS
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D018952:Antigens, CD34 / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D002051:Burkitt Lymphoma / Q000188:drug therapy; D019703:Calcineurin / Q000009:adverse effects* / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000009:adverse effects* / Q000627:therapeutic use; D006435:Renal Dialysis; D013274:Stomach Neoplasms / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D018952:Antigens, CD34; D015415:Biomarkers; D004921:Erythropoietin; D016685:Mitomycin; D019703:Calcineurin